Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of James Wentworth, PhD, MBA, as Chief Business Officer (CBO) and member of the executive management team, effective immediately. Dr. Wentworth will be responsible for developing, leading, and implementing Transgene’s business, corporate development and partnering strategi
Switzerland
France
Viropharma-europe
Transgene-euronext
Frazer-hall-sylvie-berrebi
Alessandro-riva
James-wentworth
Lucie-larguier
Syneos-health
Linkedin
University-of-bristol
Twitter